On November 12, 2020 Trobix Innovation Ltd. (Trobix Bio), an Israeli-based biotechnology company developing therapies to remove the threat of antimicrobial resistance, reported that the Israel Innovation Authority (IIA), the lead R&D supporting arm of the Israeli government, recently approved a non-dilutive grant under its "R&D fund Program", in the aggregate amount of approximately NIS 5.3M (Press release, Trobix Bio, NOV 12, 2020, View Source [SID1234644365]). This grant, alongside the recently completed funding, will be used to advance the company’s antimicrobial resistance platform technology and to further the pre-clinical development of its lead product, TBX101.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The promising achievements in our development plan have paved the way to further financial support from the IIA, which we are grateful for", said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. "The Covid-19 pandemic stresses the urgent need to tackle the global challenges of infectious diseases, and Trobix Bio is committed to developing products that can effectively tackle the imminent threat of antimicrobial resistance", he added.